Abstract: The present invention pertains to boron containing thiouracil derivatives, their method of preparations, and their use in the therapy of malignant melanoma using boron neutron capture therapy.

Abstract: A herbicidal pyrimidine derivative having the formula, ##STR1## wherein R is a lower alkyl group, and R.sup.1 is a lower alkoxy group, a halogen atom or a halogen-substituted lower alkoxy group.

Abstract: Compounds of the formula ##STR1## wherein A taken together with the two carbon atoms denoted as .alpha. and .beta. is a group of the formula ##STR2## and the dotted line is the double bond present in formulas (i) and (iii); and wherein n is zero, 1, 2 or 3, one of R.sup.1 and R.sup.2 is carboxy or alkoxycarbonyl and the other is hydrogen, R.sup.3 is hydrogen, alkyl, alkoxy, aryloxy, azido, cyano or alkylthio, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 each, independently, is hydrogen or alkyl or, when R.sup.1 is carboxy or alkoxycarbonyl and n stands for 1, R.sup.4 and R.sup.6 taken together can be a carbon-carbon bond or, when R.sup.2 is carboxy or alkoxycarbonyl, R.sup.5 and R.sup.7 taken together can be a carbon-carbon bond, R.sup.8 is halogen, alkyl, haloalkyl or alkoxy and R.sup.9 is hydrogen, halogen, alkyl or alkoxy, and pharmaceutically acceptable salts of the compounds of formula I in which one of R.sup.1 and R.sup.

Abstract: A compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are each H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are each H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo, provided that the R.sub.2 s or the R.sub.3 s are alkyl radicals; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8-positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.

Abstract: The invention relates to certain substituted fused compounds of Formula I ##STR1## which are useful as herbicides, and their agriculturally suitable compositions, as well as methods for their use as general or selective preemergent or postemergent herbicides or as plant growth regulants.

Abstract: The invention relates to an adduct-aldehyde of the general formula ##STR1## wherein R is a hydrogen atom or an optionally etherified or esterified hydroxy group,R.sub.1 is an optionally etherified or esterified hydroxy group, andZ is a sulphonyl group or a group of the general formula ##STR2## wherein A and B are equal or different and represent C.sub.1 -C.sub.4 alkoxy groups, or wherein A and B together constitute a phenylimino group or a o-phenylene group.The invention also relates to a method of preparing said adduct-aldehyde and to the use of said aldehyde as an intermediate for the preparation of vitamin-D compounds.

Abstract: Novel sulfoxide derivatives having the formula (I) 5 or (V) show a gastric acid-secretion inhibitory effect: ##STR1## wherein each of R.sup.1 and R.sup.2 is hydrogen, lower alkyl, hydroxyalkyl, phenyl, phenylalkyl or cycloalkyl, R.sup.1 and R.sup.2 may form together with the adjacent N atom a heterocyclic group; each of R.sup.3, R.sup.4, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6, and R.sup.7 is hydrogen, halogen, lower alkoxy, lower alkyl, trifluoromethyl, or fluorine atom-containing lower alkoxy; Y is CH or N; and Z is unsubstituted or substituted 2-pyridine or 2-aminophenyl.

Abstract: This invention relates to novel tricyclic derivatives of 7-substituted-6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acids and certain esters and cation salts thereof. The compounds of this invention are substituted at the 7-position by vinyl, W--CH.dbd.CH--, CH.sub.3 C.tbd.C--, W--CH.sub.2 C.tbd.C-- or ##STR1## where W is selected from certain substituted alkyl groups. This invention also relates to antibacterial compositions containing the compounds and methods of using the compounds to treat bacterial disease.

Abstract: The invention relates to new triazolyl quinoline derivatives and acid addition salts thereof whereinR.sup.1 stands for hydrogen, methyl, trihalogenomethyl or carboxy;R.sup.2 is hydrogen, halogen, C.sub.1-4 alkyl, hydroxy, C.sub.1-4 alkoxy, phenoxy, amino, acetamino, C.sub.1-4 dialkylamino, acetyl, benzoyl, methylthio, carboxy, cyano, ethoxycarbonyl, nitro or trihalogenomethyl;R.sup.3 represents hydrogen, C.sub.1-4 alkyl or C.sub.1-4 alkoxy;R.sup.4 stands for hydrogen, methyl or ethyl andX stands for a valency bond or --S--.The new compounds of the general Formula (I) ##STR1## possess valuable analgesic, antiphlogistic and fungicidal effect and can be used both in therapy and agriculture.

Abstract: 2-alkyl-4-arylmethylaminoquinolines of the general formula I ##STR1## where R.sup.1, R.sup.2, R.sup.5 and R.sup.6 have the meanings specified in the claims, and the physiologically tolerated salts thereof, the use thereof for the preparation of drugs and the drugs thus obtained as described for the inhibition of gastric acid secretion.

Abstract: A phosphorylated derivative of L-dopa of the formula ##STR1## wherein when X is ##STR2## wherein Z is --CH.sub.2, N, S or a linkage other than oxygen which renders the phosphate group resistant to hydrolysis by phosphatase enzymes in tissues and biological fluids,then Y is OQ, wherein Q is H or an alkyl with one to twelve carbon atoms, orwherein X is OQ, then Y is ##STR3## wherein R' is hydrogen or a pharmaceutically acceptable cation and R is a moiety which increases hydropobicity. The phosphorylated derivative of L-dopa is useful as an agent to increase the melanin content in mammalian skin and hair.

Abstract: Novel heterocyclic compounds, characterized in that they have formula (I) ##STR1## in which R represents a hydrogen atom, a lower alkyl radical or a phenyl or substituted phenyl radical and R.sub.1 represents an alkyl radical or an aryl radical, and their physiologically acceptable salts.

Abstract: This invention provides novel pyridonecarboxylic acid derivatives having a quite high antimicrobial activity. The derivatives have the following formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 represent each a hydrogen or C.sub.1 -C.sub.6 alkyl group; R.sup.4 represents an ethyl, 2-fluoroethyl, vinyl, isopropyl, isopropenyl or cyclopropyl group; and X represents CH, C-F, C-Cl or N wherein (i) one of R.sup.1, R.sup.2 and R.sup.3 represents a hydrogen or C.sub.1 -C.sub.6 alkyl group, and (ii) either R.sup.1 forms a methylene chain having 2 to 4 carbon atoms together with R.sup.2 or R.sup.3, or R.sup.2 and R.sup.3 form together an alkylene chain having 2 to 5 atoms and R.sup.4 represents an ethyl, 2-fluorethyl, vinyl, isopropyl, isopropenyl or cyclopropyl group and X represents CH, C-F, or C-Cl and salt thereof.

Abstract: The present invention is various 7-deazaguanines having activity as immunomodulators. Also included are pharmaceutical compositions and methods of use thereof.

Abstract: There are disclosed novel phosphorus-containing compounds including and derived from hydrogen phosphonates. The compounds of the present invention can be prepared by reacting a hydrogen phosphonate with: (a) an ethylene derivative in a Michael reaction, (b) an amine or amide and formaldehyde in a Mannich reaction, (c) an aldehyde or ketone, (d) a halogen, (e) carbon tetrachloride and an alkylamine, and (f) carbon tetrachloride and a hydroxyphosphonate. Halophosphonates produced according to procedure (d) can also be used in reactions with (a) alkylamines and (b) hydroxyphosphonates or epoxides to produce the compounds of the present invention.

Abstract: An improved process for preparing riboflavin 5'-phosphate (FMN) or its monosodium salt by reacting riboflavin with excess phosphorus oxychloride in a solvent, hydrolyzing of the resulting reaction mixture and, if desired, partially neutralizing with aqueous sodium hydroxide solution, comprises reacting the riboflavin with from 1.2 to 3 moles of phosphorus oxychloride per mole of riboflavin in a suitable lactone, especially .gamma.-butyrolactone, as solvent. The process is particularly advantageous when the reaction mixture is hydrolyzed at from 80.degree. to 90.degree. C. continuously or batchwise.

Abstract: A process for the preparation of quinolone-carboxylic acid esters of the formulae I and II ##STR1## in which A represents nitrogen or .dbd.C--R.sup.4,R.sup.4 represents hydrogen, fluorine, chlorine, nitro or methyl,B represents halogen, nitro, alkoxy, alkylsulphonyloxy or the radical ##STR2## and B additionally represents ##STR3## if R1 does not denote cyclopropyl, and R.sup.5 represents a branched or unbranched alkyl group which has 1 to 4 carbon atoms and which can optionally be substituted by a hydroxyl or methoxy group,R.sup.6 represents hydrogen, methyl or phenyl,R.sup.7 represents hydrogen or methyl,R.sup.8 represents dialkylamino having 1 or 2 carbon atoms in the alkyl group or dialkylaminomethyl having 1 or 2 carbon atoms in the alkyl group, or aminomethylR.sup.1 represents hydrogen, optionally substituted alkyl having 1 to 3 carbon atoms, optionally substituted cycloalkyl, 2-fluoroethyl, vinyl, methoxy or 4-fluorophenyl,R.sup.

Abstract: There are described compounds of the formula ##STR1## where R.sub.1 is hydrogen, loweralkyl, arylloweralkyl or aryl;R.sub.2 when present is hydrogen, loweralkyl, arylloweralkyl; andR.sub.3 is hydrogen, loweralkyl, cycloalkyl or aryl;which compounds are useful as analgesics and topical antiinflammatory agents for the treatment of skin disorders.

Abstract: The present invention is directed to a new class of 4-(oxoalkyl)phosphono, 4(oxime alkyl)phosphono, or 4-(hydrazine alkyl)phosphono, 2-piperazine carboxylic derivatives that are useful as NMDA antagonists

Abstract: A compound having the structure: ##STR1## wherein R is CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, t--C.sub.4 H.sub.9 or C.sub.6 H.sub.5 ; R.sup.1 is NH.sub.2, NHCH.sub.3, NHC.sub.2 H.sub.5, NHC.sub.3 H.sub.7, NHC.sub.4 H.sub.9, NHCH.sub.2 CH.sub.2 Cl, NHC.sub.6 H.sub.5, N(CH.sub.3).sub.2, N(C.sub.2 H.sub.5).sub.2, N(C.sub.3 H.sub.7).sub.2, NCH.sub.3 (C.sub.2 H.sub.5), NCH.sub.3 (C.sub.3 H.sub.7), N(CH.sub.2 CH.sub.2 Cl).sub.2, NHOH, NHNHCO.sub.2 CH.sub.2 C.sub.6 H.sub.5, NHNHCO.sub.2 C(CH.sub.3).sub.3, OCH.sub.3, OC.sub.2 H.sub.5, OC.sub.3 H.sub.7, OC.sub.4 H.sub.9, OC.sub.6 H.sub.5, OC.sub.2 C.sub.6 H.sub.5, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9, CH.sub.2 NO.sub.2 or CH.sub.2 NH.sub.2 ; and R.sup.2 is NHCH.sub.2 CH.sub.2 Cl or N(CH.sub.2 CH.sub.2 Cl).sub.2.These compounds may be used to eliminate occult leukemic clonogenic cells from bone marrow by contacting the bone marrow with a solution comprising levels of said compound sufficient to eliminate occult leukemic clonogenic cells.